期刊
ONCOTARGET
卷 5, 期 9, 页码 2839-2852出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.1943
关键词
cholangiocarcinoma; next-generation sequencing; molecular subclassification; target therapy; multigene mutational panels
资金
- GlaxoSmithKline [WEUSKOP5847]
- AIRC [12182, 11930, 6421]
- National Cancer Institutes (USA) [CA62924]
- FP7 EU project CAM-PaC [602783]
- Italian Cancer Genome Project grant from the Italian Ministry of Research [FIRB - RBAP10AHJB]
- FIMP-Ministry of Health [CUP_ J33G13000210001]
One-hundred-fifty-three biliary cancers, including 70 intrahepatic cholangiocarcinomas (ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 gallbladder carcinomas (GBC) were assessed for mutations in 56 genes using multigene next-generation sequencing. Expression of EGFR and mTOR pathway genes was investigated by immunohistochemistry. At least one mutated gene was observed in 118/153 (77%) cancers. The genes most frequently involved were KRAS (28%), TP53 (18%), ARID1A (12%), IDH1/2 (9%), PBRM1 (9%), BAP1 (7%), and PIK3CA (7%). IDH1/2 (p = 0.0005) and BAP1 (p = 0.0097) mutations were characteristic of ICC, while KRAS (p = 0.0019) and TP53 (p = 0.0019) were more frequent in ECC and GBC. Multivariate analysis identified tumour stage and TP53 mutations as independent predictors of survival. Alterations in chromatin remodeling genes (ARID1A, BAP1, PBRM1, SMARCB1) were seen in 31% of cases. Potentially actionable mutations were seen in 104/153 (68%) cancers: i) KRAS/NRAS/BRAF mutations were found in 34% of cancers; ii) mTOR pathway activation was documented by immunohistochemistry in 51% of cases and by mutations in mTOR pathway genes in 19% of cancers; iii) TGF-beta/Smad signaling was altered in 10.5% cancers; iv) mutations in tyrosine kinase receptors were found in 9% cases. Our study identified molecular subgroups of cholangiocarcinomas that can be explored for specific drug targeting in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据